We show here that the rat vasopressin V 1b receptor simultaneously activates both the G q/11 -inositol phosphate (IP) and G s -cAMP pathways when transiently expressed in Chinese hamster ovary, human embryonic kidney (HEK) 293, and COS-7 cells and stimulated with arginine-vasopressin. Higher concentrations of the hormone, however, were needed to trigger the cAMP pathway. The nonmammalian analog argininevasotocin and the selective V 1b agonist d [Cha 4 ]vasopressin also activated the cAMP and IP pathways, although d [Cha 4 ]-vasopressin elicited the two responses with equivalent potencies. We determined that the V 1b receptor is present as a homodimer at the plasma membrane. Treatment of V 1b -transfected HEK-293 cells with methyl-␤-cyclodextrin, a drug known to dissociate cholesterol-rich domains of the plasma membrane, shifted the EC 50 of the vasopressin-induced cAMP accumulation to lower concentrations and, remarkably, increased the hormone efficacy related to the activation of this second messenger system. In parallel, the vasopressin-mediated activation of the IP pathway was slightly reduced without modification of its EC 50 . These results suggest that, as with many other G protein-coupled receptors, when transfected in heterologous cell systems, the V 1b receptor forms dimers that signal differentially through the G q/11 and G s proteins depending on the nature of the ligand as well as on its localization within specialized compartments of the plasma membrane. The present study thus illustrates how signal transduction associated with the activation of a G protein-coupled receptor can be versatile and highly dependent on both the cell context and the chemical nature of the extracellular signaling messenger.
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Increasing evidence indicates that G protein-coupled receptor (GPCR) signaling can achieve specificity in different ways. The previously accepted linear signaling concept has evolved into a network concept that allows for more possibilities with respect to the fine tuning of various pathways. The differential activation or inactivation of G protein-dependent or -independent signaling pathways can occur at various levels (Hermans, 2003; Swaminath et al., 2005; Michel and Alewijnse, 2007) . First, receptors can adopt different active and inactive conformational states depending on the ligands they bind, resulting in multiplicity of coupling (Kenakin 2003) . Second, GPCRs have the propensity to homo-or heterodimerize, leading to variations in their pharmacological properties (Terrillon and Bouvier, 2004; Park and Palczewski, 2005; Milligan, 2006) . Finally, the receptor environment, in particular the localization of receptors within specialized microdomains of the plasma membrane such as rafts or caveolae, can profoundly modify their coupling properties and cause them to switch from one signaling pathway to another (Gimpl and Fahrenholz, 2000; Guzzi et al., 2002; Rimoldi et al., 2003) . All of these aspects can contribute to the interaction of GPCRs with different protein complexes and can thus explain cell-dependent signaling variability and how signaling can be channeled into specific routes in particular cells (Schulte and Levy, 2007) . Accordingly, such aspects must be taken into consideration to have a complete understanding of a given receptor's cellular lifespan and to develop new selective therapeutic compounds.
We have focused our work on the arginine-vasopressin (AVP) V 1b receptor. This GPCR, which is expressed in numerous peripheral tissues (e.g., pituitary gland and adrenal gland) and various areas of the nervous system (Lolait et al., 1995; Hurbin et al., 1998; Vaccari et al., 1998; Hernando et al., 2001; Young et al., 2006) , is involved in stress behavior and represents an interesting therapeutic target for psychiatric disorders such as anxiety or depression (Serradeil-Le Gal et al., 2002) . In this context, studying its functional activation properties is of importance.
Previous studies have suggested that the V 1b receptor can exhibit differential coupling, as has been shown for other members of the AVP/oxytocin (OT) receptor family (V 1a , V 2 , and OT receptors). Indeed, other members of the family signal either through pathways involving different G proteins (Abel et al., 2000; Zhou et al., 2007) or even through G protein-independent pathways (Rimoldi et al., 2003; Charest et al., 2007) . With respect to the V 1b receptor, previous work has shown that it activates the IP pathway via coupling to the G q/11 protein (Jard et al., 1986) . Signaling through the cAMP pathway has been reported in stably transfected CHO cells, although it was interpreted as nonspecific coupling to G s caused by overexpression (Thibonnier et al., 1997) . In addition, an atypical response of the V 1a and/or V 1b receptors toward the cAMP pathway was suspected in the vasopressinergic magnocellular neurons of the supraoptic nucleus (Hurbin et al., 1998) . Specifically, AVP triggered an adenylyl cyclase-mediated intracellular response in these cells through a mechanism that is not yet understood because the G s -coupled V 2 receptor is not expressed (Hurbin et al., 1998; Sabatier et al., 1998; Gouzénes et al., 1999) .
To investigate the potential multiple coupling properties of the rat V 1b receptor, we sought to determine whether 1) this receptor could activate both the IP and cAMP signaling pathways at low levels of expression and in different cell systems, 2) a link could be established between the nature of the ligand on the one hand and the signaling pathway activated or intensity of the response on the other hand, 3) the receptor could form dimers at the cell surface, and 4) the response depended on the localization of the receptor within specialized plasma membrane microdomains.
Materials and Methods
cDNA constructs. Rat AVP V 1b receptor cDNA was obtained by RT-PCR. Total RNA was extracted from carefully dissected rat pituitary glands using the RNeasy kit (QIAGEN, Courtaboeuf, France). Forward (5Ј-CACCTCTAAACCTTTCTCTCTCATTCC-3Ј) and reverse (5Ј-GGATTGAGTGCTCTGATTTCCAAC-3Ј) V 1b -specific primers were synthesized by Sigma Genosys (St-Quentin-Fallavier, France). Reverse transcription was performed on RNA extracts previously digested with deoxyribonuclease I (Invitrogen, Cergy-Pontoise, France), using SuperScript II reverse transcriptase (Invitrogen), RNAsin (Promega Corp, Charbonnières, France) as an RNase inhibitor, and the reverse primer. DNA amplification was performed using a PTC-150/16 thermal controller (MJ Research, Inc., Watertown, MA), Platinum Pfx DNA polymerase (Invitrogen), the reverse primer previously used for reverse transcription, and the forward primer. N-terminal tags (hexahistidine, 6ϫHis tag; or hemagglutinin, HA tag) were introduced in a second PCR step using specific primers designed to also add two restriction sites (5Ј-BamHI and 3Ј-XhoI) to control the direction of fragment insertion. The PCR products were electrophoresed on a 1% agarose gel in Tris-acetate/ EDTA buffer (40 mM Tris-acetate and 1 mM EDTA, pH 8) and purified using GenElute columns (Sigma). Double digestion of the DNA ends with BamHI and XhoI was performed, and the main fragment containing the V 1b coding sequence was purified and ligated with T4 DNA Ligase (Roche, Meylan, France) into pcDNA3.1(ϩ) vector (Invitrogen) that had been digested with the same restriction enzymes and dephosphorylated using alkaline phosphatase (Roche). The sequence was verified by sequencing of both strands (Genome Express, Meylan, France). Using the same procedure, rat AVP V 1a receptor cDNA was prepared using specific forward (5Ј-CCTCAGGACCAGACAGAAGTAGG-3Ј) and reverse (5Ј-CCACATAAACACATCTGCTCTTACG-3Ј) primers and RNA extracted from liver. The N-terminal 6ϫHis-tag and restriction sites (5Ј-BamHI and 3Ј-XhoI) were then added by PCR, and the sequence was inserted by T4 ligation into the pcDNA3.1(ϩ) vector as indicated above.
Cell Culture and Transfection. Cell lines were obtained from the American Type Culture Collection (Manassas, VA). Cell culture media, fetal bovine serum (FBS), and additives were provided by Invitrogen.
CHO, HEK-293, and COS-7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 100 U/ml penicillin/streptomycin, and 2 mM L-glutamine, at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . For the CHO cell line, nonessential amino acids (Invitrogen) were also added to the media.
Transient transfection of the cell lines was performed using electroporation in a 300-l volume with a total of 10 g of DNA (V 1b plasmid up to 1 g plus pcDNA3.1 as carrier DNA to reach 10 g) containing 10
7 cells in electroporation buffer (50 mM K 2 HPO 4 , 20 mM CH 3 COOK, 20 mM KOH, and 26 mM MgSO 4 , pH 7.4). After electroporation (260-280 V, 1 mF, GeneZapper 450/2500; IBI, New Haven, CT), cells were suspended in complete medium and seeded into 96-well culture plates at a density of 10 5 (ELISA and cAMP pathway test) or 8 ϫ 10 4 (IP pathway test) cells per well. Ninety-sixwell culture plates were first coated with polyornithine diluted in PBS, incubated at 37°C for 1 h, and then rinsed with PBS before seeding. Twenty-four hours after transfection, receptor expression was measured by radioligand binding assay or ELISA, and the experiments on receptor dimerization and signaling pathways were performed. To improve the expression of the transfected receptors, CHO and HEK-293 cells were incubated overnight with 3 mM sodium butyrate before the experiments. This treatment was not necessary with the COS-7 cells.
ELISA. To measure the expression of the transfected receptors, cells were fixed with 4% paraformaldehyde in PBS for 5 min and rinsed three times with PBS. A blocking step of 30 min with PBS ϩ 1% decomplemented FBS was performed before incubation with the primary antibodies (0.5 g/ml) for 30 min. The cells were then rinsed four times for 5 min in PBS ϩ 1% FBS and incubated for 30 min with an anti-mouse antibody conjugated with horseradish peroxidase (1/1000; Amersham, Orsay, France). The cells were rinsed three times with PBS ϩ 1% FBS and three times with PBS. Afterward, 60 l of PBS and 20 l of Supersignal ELISA Femto (Perbio-Pierce, Brebières, France) were added to the wells. The luminescence was read using a Wallac Victor 2 (PerkinElmer Life and Analytical Sciences, Courtaboeuf, France).
Second Messenger (IP 1 and cAMP) Accumulation. Activation/inhibition of the IP and cAMP pathways by AVP receptor agonists or antagonists, respectively, was determined using the IP-One and cAMP dynamic kits (Cisbio Bioassays, Bagnols-sur-Cèze, France Ro-20-1724 (Calbiochem, Darmstadt, Germany) , prevents cAMP degradation. The homogeneous time-resolved fluorescence-fluorescence resonance energy transfer (HTRF-FRET) assay was performed as described previously (Maurel et al., 2004) . This assay involves the transfer of energy from a europium cryptate pyridine-bipyridine donor fluorophore to a d2 acceptor fluorophore. The assay is an immunoassay that measures competition between native IP 1 or cAMP produced by the cells and IP 1 -or cAMP-labeled with the d2 acceptor, as revealed by a monoclonal antibody against IP 1 or cAMP labeled with europium cryptate pyridine-bipyridine. Twenty-five microliters of antibody and 25 l of competitor diluted in lysis buffer provided in the kits were added to the wells after 30-min incubation at 37°C with the agonist. As a negative control, some wells only received the donor fluorophore-labeled antibody. After 1 h incubation at room temperature, fluorescence emissions were measured at both 620 and 665 nm on a RubyStar fluorometer (BMG Labtechnologies, Offenburg, Germany) equipped with a nitrogen laser as the excitation source (337 nm). A 400-s reading was recorded after a 50-s delay to eliminate the short-lived fluorescence background from the acceptor fluorophore-labeled antibody. The fluorescence intensities measured at 620 nm and 665 nm correspond to the total europium cryptate emission and to the FRET signal, respectively. The specific FRET signal was calculated using the following equation: ⌬F% ϭ 100 ϫ (R pos Ϫ R neg )/(R neg ), with R pos being the fluorescence ratio (665/620 nm) calculated in wells incubated with both donor-and acceptor-labeled antibodies, and R neg being the same ratio for the negative control incubated only with the donor fluorophore-labeled antibody. The FRET signal (⌬F%), which is inversely proportional to the concentration of IP 1 or cAMP in the cells, was then transformed into IP 1 or cAMP accumulation using a calibration curve prepared on the same plate. It is worth noting that all comparisons of agonist or antagonist effects were done on the same day, on the same culture and plate, and were made against the AVP effect. The experiments were repeated at least three times on different cultures. Normalization was performed as indicated in the figure legends, either as a percentage of the maximal value or as a percentage of the maximal value for AVP when comparisons were necessary. Values corresponding to the low basal activities, determined in unstimulated cells, were first subtracted. Activation/inhibition curves were plotted to the log of agonist or antagonist concentrations and fitted to the Hill equation to extract the EC 50 , Hill coefficient, and minimal/maximal values.
Overnight preincubation of cells with either cholera toxin (Ctx) (20 g/ml culture medium) or pertussis toxin (Ptx) (100 ng/ml culture medium) was used to test the involvement of the G s and G i proteins in V 1b receptor cAMP signaling in response to AVP. When used to directly activate adenylyl cyclase, forskolin was added for 30 min at 50 M.
The inhibitory effect of the specific nonpeptidic V 1b antagonist, SSR149415 (Serradeil-Le Gal et al., 2002) , on IP 1 and cAMP accumulations induced by AVP was studied according to Arunlakshana and Schild (1959) . Preincubation for 10 min with the antagonist was followed by 30-min incubation with the antagonist and AVP. Concentrations of AVP greater than 1 M were not tested here and more generally in this study because, in our experimental conditions, they often led to nonspecific effects. Therefore, we cannot formally insure that the inhibition by SSR149415 is strictly competitive.
Incubation of cells with methyl-␤-cyclodextrin (M␤CD; Sigma) was used to study how removing cholesterol from the plasma membrane affects V 1b receptor signaling. Preincubation at 37°C for 10 min with 10 mM M␤CD in incubation medium was followed by 30 min incubation with 10 mM M␤CD plus the agonist serial dilutions. IP 1 and cAMP accumulations were then measured as described above.
RT-PCR. We performed RT-PCR on RNA extracts of COS-7 cells (which are derived from Chlorocebus aethiops, African green monkey) to detect the suspected expression of endogenous AVP V 2 receptor mRNA. Forward (5Ј-GCTAGTGATTGTGGTCGTCTATGTGC-3Ј) and reverse (5Ј-CACGCTGCTGCTGAAAGATGC-3Ј) primers were designed based on the human V 2 receptor sequence to amplify a 178-bp band from the three primate V 2 receptor sequences available to date (Homo sapiens, Pan troglodytes, Macaca mulatta). An intron lies between the two primer sites to ensure the rejection of undesired amplification of any residual genomic DNA. RT-PCR was performed as described above.
Radioligand Binding Assays to Intact Cells. The first binding assay was carried out with [ 3 H]AVP to determine the amount of functional receptor present at the plasma membrane of transfected CHO and HEK-293 cells. After electroporation, cells were seeded in 24-well plates at a density of 4 ϫ 10 5 cells/well. Binding assays were performed after 24 h. Cells were washed twice in ice-cold Tris/Krebs buffer (20 mM Tris-HCl pH 7.4, 118 mM NaCl, 5.6 mM glucose, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 4.7 mM KCl, and 1.8 mM CaCl 2 ) with 0.1% bovine serum albumin (BSA), after which each well received 0.2 ml of ice-cold Tris/Krebs buffer ϩ 0.1% BSA ϩ 5 mM phenylalanine and the appropriate dilution of [ 3 H]AVP (0.25 to 8 nM). Plates were incubated for 4 h in the cold room before removal of the binding mixture by aspiration. After quickly rinsing three times with ice-cold Krebs buffer ϩ 0.1% BSA, 0.3 ml of 0.1 N NaOH was added to each well to lyse the cells and extract the radioactivity. The fluid from the wells was then neutralized, transferred to scintillation vials, and counted on a ␤-counter (Tri-Carb 2100TR; PerkinElmer Life and Analytical Sciences). Nonspecific binding was determined under the same conditions in the presence of 10 M unlabeled AVP. Protein levels were determined using the BCA protein assay (Pierce Biotechnology, Rockford, IL). The experiment was repeated three times on different cultures. Maximal binding capacity and dissociation constants were determined from the Scatchard transformation of the saturation binding curves.
The second binding assay was done to determine, through a competition experiment, the inhibitory dissociation constant (K i ) of arginine-vasotocin (AVT) for the rat AVP V 1b receptor. Cells were incubated with a fixed concentration of [ 3 H]AVP (2 nM) that was displaced using increasing concentrations of AVT (10 Ϫ12 to 10 Ϫ6 M). The experiment was repeated three times on different cultures. Displacement curves were fitted to determine the IC 50 values, which were then converted to K i using the Cheng-Prusoff equation: Receptor Dimerization at the Plasma Membrane. Dimerization was measured using an HTRF-FRET assay. Monoclonal anti6ϫHis and/or anti-HA antibodies labeled with a europium cryptate pyridine-bipyridine donor fluorophore or a d2 acceptor fluorophore (Cisbio Bioassays) were used. After transfection, 10 5 COS-7 cells/well were transferred to a black 96-well assay plate (Greiner Bio-One) in 100 l of complete medium. Twenty-four hours later, COS-7 cells expressing the 6ϫHis-or HA-tagged rat receptors were incubated at 4°C in 100 l of Tris/Krebs buffer supplemented with 0.1% BSA and containing 1 nM europium cryptate pyridine-bipyridine-and 1 nM d2-labeled antibodies. To obtain the negative control value, some COS-7 cells were incubated with the donor fluorophore-labeled antibody only. Fluorescence intensities were measured at 620 and 665 nm and the FRET signal (⌬F%), reflecting dimerization, calculated as described above. The experiments were repeated at least three times on different cultures.
Statistical Analysis. Statistical significance of the differences between experimental groups was determined by one-way or twoway analysis of variance followed by a post hoc Duncan's multiple range test to make pairwise comparisons between means. Student's t test was also used.
Results
The Rat V 1b Receptor Signals through Both the IP and cAMP Pathways. AVP stimulation of CHO, HEK-293, and COS-7 cells transfected with 1 g of rat V 1b receptorencoding plasmid led to the activation of both the IP and cAMP pathways measured as accumulation of IP 1 and cAMP, respectively (Fig. 1) . The responses were specific for V 1b receptor expression, because mock CHO and HEK-293 cells (transfected with an empty pcDNA3 vector) exhibited no response to AVP (Fig. 1, A and B) . Similar patterns of IP 1 and cAMP accumulation were observed with transiently transfected COS-7 cells (Fig. 1C) , despite the presence of endogenous V 2 receptor, which was responsible for approximately 20% of the cAMP production as demonstrated in mock cells. The presence of this endogenous receptor was confirmed by RT-PCR performed using primers specific for primate V 2 receptor sequences, revealing the endogenous V 2 receptor mRNA in COS-7 cell extracts (data not shown).
The dual coupling was not due to overexpression of V 1b receptors (448 ϫ 10 3 receptors/cell compared with 36 ϫ 10 3 receptors/cell in corticotrophs of the adenohypophysis; Gaillard et al., 1984) because it was still observed when lowering V 1b receptors expression (31 ϫ 10 3 receptors/cell) to a level similar to that of the physiological one (Supplemental Fig. 1) .
Differential Activation of IP and cAMP Pathways after AVP Stimulation. Although AVP stimulated both the IP and cAMP signaling pathways, it is worth noting that in the three cell lines tested AVP stimulated the accumulation of IP 1 at lower concentrations than that of cAMP (Fig. 1,  A-C) . Specifically, as shown in Table 1 , the EC 50 values for the IP accumulation, which were very close to the K d values, were consistently three to five times lower than those obtained for the cAMP accumulation. This has been observed whatever the V 1b receptor expression level. Moreover, in both CHO and HEK-293 cells, where no endogenous V 2 receptor TABLE 2 Characteristics of the response curves to different antagonist or agonists in CHO cells transfected with rat V 1b receptor-encoding DNA The K inact of SSR149415 were derived from the pA2 of the Arunlakshana-Schild plots (Fig. 3) disturbs the response, the Hill coefficients of the activation curves were lower for the IP pathway than for the cAMP pathway. Reliable similar analyses of COS-7 cell parameters were not possible because of the presence of endogenous V 2 receptor.
To confirm that the cAMP pathway is directly stimulated by the V 1b receptor, we examined the involvement of G s . Specifically, we treated transfected CHO cells overnight with Ctx to induce direct and sustained stimulation of G s . As expected, under these conditions, cAMP accumulation was much higher, but AVP had no additive effect ( Fig. 2A) . This absence of effect of AVP under Ctx treatment was not due to saturation of adenylyl cyclase activity, because simultaneous treatment of the cells with Ctx and forskolin further increased cAMP accumulation (by 53.0 Ϯ 4.2 times; data not shown). It can thus be inferred from these two observations that the stimulation of the V 1b receptor by AVP requires the G s protein to activate the cAMP pathway. By contrast, the V 1b receptor did not stimulate the G i or G o protein, because an overnight treatment with Ptx did not affect the AVPinduced cAMP accumulation (Fig. 2B) . As a positive control, such a treatment inhibited the serotonin-induced response of the G i -coupled human 5HT 1a receptor (Supplemental Fig. 2) .
AVP Analogs Activate the IP and cAMP Pathways in Different Manners. To address whether the two signaling pathways exhibit different pharmacological properties, we examined the effects on both pathways of one specific nonpeptidic V 1b antagonist, SSR149415 (Serradeil-Le Gal et al., 2002), and two peptidic agonists of AVP, arginine-vasotocin (AVT), the nonmammalian vertebrate ortholog of AVP, and d [Cha 4 ]AVP, a specific V 1b receptor agonist (Guillon et al., 2006) . IP 1 and cAMP accumulations in V 1b -transfected CHO cells stimulated with increasing AVP concentrations was studied without or with increasing amounts of SSR149415. The resulting Arunlakshana-Schild plots showed that both the IP and cAMP pathways were turned off (Fig. 3) . It is noteworthy that the antagonist affected the cAMP accumulation at lower concentrations (pA 2 ϭ 9.99; i.e., K inact ϭ 0.10 nM) than the IP 1 accumulation (pA 2 ϭ 9.14; i.e., K inact ϭ 0.72 nM) ( Fig. 3 ; Table 2) .
Although the two agonists tested, AVT and d [Cha 4 ]AVP, stimulated both pathways, the curves differed from those obtained with AVP (Fig. 4) . As with AVP, AVT activated both the IP and cAMP pathways, but did it with lower EC 50 values than AVP ( Fig. 4A; Table 2 ). Again, it is worth noting that the EC 50 of the IP 1 accumulation curve was lower than that of the cAMP one and was very close to the affinity of AVT for the V 1b receptor measured in binding experiments ( Table 2 ). The stimulation of IP signaling by AVT was similar to that by AVP with respect to the slopes of the curves (Table 2 ) and the maximal stimulation values (Table 2) . By contrast, cAMP stimulation by AVT differed from that by AVP in that it had a steeper slope ( Fig. 4A ; Table 2 ) and showed a 36% higher level of maximal stimulation (Table 2) . AVT is thus a more potent and more efficacious agonist than AVP on the cAMP pathway.
d [Cha 4 ]AVP also activated both the IP and cAMP pathways, but did not show any differences in the activation of the two pathways, and the dose-response curves for IP 1 and cAMP accumulation were superimposed (Fig. 4B) . In both cases, high concentrations of d [Cha 4 ]AVP were necessary to elicit the response ( Fig. 4B; Table 2 ), even though the affinity of this compound for the rat V 1b receptor is known to be 1.4 nM in CHO cells (Guillon et al., 2006) . Both curves exhibited a slope factor of around 1 and lower maximal stimulation levels than those observed with AVP (Ϫ18 and Ϫ59% for the IP and cAMP pathways, respectively; Table 2 ). Therefore, d [Cha 4 ]AVP was shown to be a partial agonist of the IP and cAMP pathways compared with AVP or AVT.
Dimers of Rat V 1b Receptors Detected at the Plasma Membrane. Slope factors greater than 1 (1.67 for AVT on cAMP accumulation) or less than 1 (AVP and AVT on IP 1 accumulation) were observed. Among other hypotheses, such as binding site heterogeneity of the ligand for the receptor and/or of the ligand-receptor complexes for G proteins, these slope factors different from 1 strongly suggested the existence of cross-talk between receptors, dimers, or oligomers. Because cross-talk between receptors has been related to dimerization in various reports (Terrillon and Bouvier, 2004; Park and Palczewski, 2005; Milligan, 2006; Urban et al., 2007) , we tested whether the rat V 1b receptor is able to dimerize at the plasma membrane. DNA encoding the rat V 1b receptor, tagged with the 6ϫHis epitope at the extracellular N terminus, was transiently transfected into COS-7 cells and HTRF technology used to quantify dimers at the cell surface. As a positive control for dimerization, COS-7 cells from the same culture were transfected with a rat V 1a receptor that had similarly been tagged with the 6ϫHis epitope. In both cases, a FRET signal was observed for the V 1a receptor (⌬F ϭ 236%) and the V 1b receptor (⌬F ϭ 128%) (Fig. 5A ) when expressed at similar levels (Fig. 5B) . The specificity of the FRET signal was demonstrated by 1) the absence of signal in mock cells; 2) the relationship between the amount of V 1b receptor expressed at the membrane and the FRET signal: SSR149415 (1 M, overnight), by acting as a pharmacochaperone on the receptor, thus facilitating its targeting to the cell membrane (Robert et al., 2005) , increased membrane V 1b receptor by 61% (measured by ELISA; Fig. 5, B and D) and the FRET signal by 57% (Fig. 5, A and C) ; and 3) the weak FRET signal observed (⌬F ϭ 16%) between an HA-tagged human GABA B2 receptor (a member of the GPCR C family) and the 6ϫHis-tagged V 1b receptor compared with the signal obtained with the HA-V 1b and 6ϫHis-V 1b receptors (71%) (Fig. 5C ). The weak signal was not due to low HA-GABA B2 receptor expression, because the HA-GABA B2 and HA-V 1b receptors were expressed at similar levels (Fig. 5D) . Instead, it probably resulted from the simple promiscuity of the receptors.
Lowering Plasma Membrane Cholesterol Modifies V 1b Receptor Signaling. The OT receptor has been shown to activate both the G q/11 and G i pathways, and these dual properties are dependent on the localization of the receptor to specialized domains of the plasma membrane (Gimpl and Fahrenholz, 2000; Guzzi et al., 2002; Rimoldi et al., 2003) . We thus decided to investigate whether the activation levels of the two signaling pathways triggered by stimulating the V 1b receptor would be similarly affected by alterations in receptor localization within different membrane compartments. Because we had observed that AVP-induced IP 1 accumulation was quite similar in the CHO and HEK-293 cell lines, whereas AVP-induced cAMP accumulation differed strongly between the two cell types, we compared the effects of M␤CD, a compound known to rapidly remove more than half of the cholesterol from the plasma membrane (Kilsdonk et al., 1995) , on these two cell lines.
CHO cells expressing the rat V 1b receptor were incubated with 10 mM M␤CD. Under these conditions, the maximal AVP-induced IP 1 accumulation was significantly reduced (Ϫ30% at maximal effect), whereas the maximal cAMP accumulation was increased (ϩ10% at maximal effect) (data not shown).
The experiments were then repeated in HEK-293 cells transfected with the V 1b receptor, in which only a low level of cAMP accumulation by AVP was initially observed (Table 1) . When these cells were stimulated with AVP in the presence of 10 mM M␤CD, IP 1 accumulation fell by 32% at maximal effect, similar to what was observed in CHO cells ( Fig. 6A ; Table 3 ). The cAMP accumulation, in contrast, showed a much higher level of activation (ϩ234% at saturation) than it did in the absence of M␤CD ( Fig. 6B ; Table 3 ). The M␤CD treatment of HEK-293 cells did not change significantly the EC 50 of the AVP-induced IP 1 accumulation (Table 3) . It is noteworthy that the EC 50 of the AVP-induced cAMP accumulation shifted significantly from 32.7 to 13.1 nM after (1 M, overnight) . B, corresponding 6ϫHis-ELISA signal in the cells transfected with 6ϫHis-V 1b receptor-encoding DNA. C, negative control for dimerization. FRET signal between HA-and 6ϫHis-tagged V 1b receptors, and between HA-GABA B2 (GB 2 ) receptor and 6ϫHis-V 1b receptor, after cotransfection in COS-7 cells treated or not with the V 1b -specific antagonist (SSR149415). D, corresponding HA-ELISA signal. Despite an essentially equivalent ELISA signal at the plasma membrane, the GB 2 receptor only gave a very low M␤CD treatment. The same effects on IP 1 (Ϫ31%) and cAMP (ϩ265%) accumulations were obtained when V 1b receptortransfected HEK-293 cells were stimulated with AVT instead of AVP (Fig. 6 , C and D; Table 3 ). When d [Cha 4 ]AVP was used to stimulate the cells, cAMP accumulation was also highly increased by M␤CD treatment; as in CHO cells, activation of both pathways were observed at higher similar concentrations (Fig. 6, E and F; Table 3 ). Together, these results clearly indicated that compartmentalization of the V 1b receptor in cholesterol-rich specialized domains modulates its G protein-dependent signalization.
Finally, to investigate the possibility that treatment of the cells with M␤CD directly affected adenylyl cyclase activity, wild-type HEK-293 cells were stimulated with forskolin with or without treatment with M␤CD. M␤CD did not change the level of cAMP accumulation (Fig. 6G ).
Discussion
We observed dual signaling activity for the V 1b receptor; it activated both the IP pathway, as expected (Jard et al., 1986) , and the cAMP pathway through coupling to the G s protein. Coupling to G i , in contrast, was not observed. These results were not cell-line-dependent, in that they were ob- Post hoc Duncan's multiple range test for difference between means: A, p Ͻ 0.05 for Ϫ9 and Ϫ8.5, p Ͻ 0.001 for Ϫ8 to Ϫ6; B, p Ͻ 0.001 for Ϫ8.5 to Ϫ6; C, p Ͻ 0.01 for Ϫ8.5, p Ͻ 0.001 for Ϫ8 to Ϫ6; D, p Ͻ 0.001 for Ϫ8.5 to Ϫ6; E, p Ͻ 0.01 for Ϫ7, p Ͻ 0.001 for Ϫ6.5 and Ϫ6; F, p Ͻ 0.05 for Ϫ9, p Ͻ 0.01 for Ϫ8, p Ͻ 0.001 for Ϫ7.5 to Ϫ6; two-way analysis of variance for G (M␤CD versus forskolin), not significant. tained in the three different cell lines tested. Moreover, at variance with previously reported results (Thibonnier et al., 1997) , we observed that the dual signaling of the V 1b receptor is not restricted to cells in which the receptor is overexpressed (Ͼ25 pmol/mg protein), but is also observable at receptor densities in the same range as those observed in native tissues. This dual signaling was observed with various agonists, albeit with some notable differences in the activation curves. For example, although the EC 50 values for AVP or AVT activation of the IP pathway were very close to their binding affinities, for cAMP pathway activation, the EC 50 values were three to five times higher. By contrast, the EC 50 values of d [Cha 4 ]AVP for the IP and cAMP pathways were consistently higher than the affinity constants. Dual signaling has been observed previously for many GPCRs, and in some cases, such as the corticotropin-releasing hormone receptor or the luteinizing hormone receptor, coupling to even three G proteins has been described previously (Hermans, 2003) . In most cases, and as observed here also, the coupling occurs at different concentrations (Ashkenazi et al., 1987) . In rare cases, such as here with d [Cha 4 ]AVP, activation of the two pathways occurs at the same ligand concentration (Cussac et al., 2002) . Regarding the AVP/OT receptor family, dual G protein coupling has been reported for the V 1a (Abel et al., 2000) and OT receptors (Strakova and Soloff, 1997) , both of which couple to G q/11 and G i . In addition, the V 2 receptor possibly activates G s and G q/11 (Liu and Wess, 1996) .
Although the concomitant activation of different signaling pathways has been well established, the molecular mechanisms underlying differential coupling remain unclear. A few hypotheses have been formulated to explain this phenomenon. Dual signaling and a shift between two activation curves may be explained by a difference in the affinity of the ligand-receptor complex for each G protein, or by a difference in the relative concentrations of the G proteins (Kenakin, 2003) . In addition, cross-talk between ligands, receptors, and G proteins can influence the conformations of the different partners and lead to significant differences in receptor signaling (Kenakin, 2003) .
The first and probably simplest hypothesis is that the affinities of the receptor-G protein complex for the ligand are dependent on the nature of the G protein. For example, stimulation of the IP pathway by AVP and AVT could result from the binding of the ligand to the high-affinity binding sites, whereas the cAMP pathway could be activated by the binding of the ligand to the low-affinity binding sites. However, this hypothesis is not completely in accordance with different data: 1) the curves of IP 1 accumulation exhibit slope factors of around 0.7 to 0.8, indicating either negative cooperative binding or the coexistence of independent high-and low-affinity binding sites that both couple to the IP signaling pathway; 2) the d [Cha 4 ]AVP-induced accumulation of both IP 1 and cAMP is shifted to the right of the binding curve, suggesting that the high-affinity binding sites are devoid of any activity and that low-affinity binding sites are involved in both coupling pathways; and 3) the AVT-induced cAMP pathway activation curves are steep, indicating a positive cooperative effect.
Because positive and negative cooperative effects have been related to receptor dimerization (Durroux, 2005; Urizar et al., 2005; Springael et al., 2006) , we investigated the ability of rat V 1b to undergo oligomerization. The AVP V 1a and V 2 receptors, as well as the OT receptor, have previously been shown to homo-and heterodimerize (Terrillon et al., 2003) . Using the HTRF method and conjugated antibodies against extracellular epitopes, we have now been able to detect homodimers of V 1b receptors at the plasma membrane of transfected cells. Because saturation and homologous competition experiments performed on the human V 1b receptor using radioligands have clearly demonstrated negative cooperative binding (Albizu et al., 2006) , the activation of the two signaling pathways could be related to ligand-receptor stoichiometry. Moreover, as with other GPCRs, changes in V 1b receptor conformation upon agonist binding may differ considerably with respect to the ligand structure, the cooperativity between the two protomers in the dimer, their affinities for different G proteins, and/or their abilities to activate bound G proteins (Michel and Alewijnse, 2007; Urban et al., 2007) . In accordance with the receptor dimerization hypothesis, the IP pathway could be activated by the binding of either one or two AVP molecules to a single receptor dimer. Because of the negative cooperative binding, the activation curve would thus exhibit a slope of less than 1. By contrast, cAMP production could only be turned on upon the binding of two ligands to a dimer. Because of the negative cooperative binding, the cAMP activation curve would be observed only during the saturation of the low-affinity binding sites and would thus exhibit a slope factor of around 1; it would therefore be shifted to the right of the IP activation curve. Contrary to AVP and AVT, two d [Cha 4 ]AVP molecules would need to bind to the receptor to induce an active receptor conformation, whatever the signaling pathway considered. Consistent with these hypotheses, the SSR149415 antagonist shuts down the cAMP pathway as soon as one AVP ligand is displaced but does not inactivate the IP pathway until both ligands are removed. GPCR signaling has been shown to be related to the compartmentalization of receptors or G proteins within specialized microdomains of the plasma membrane. For example, the OT receptor is able to signal through G q/11 or G i depending on its localization within or outside of cholesterol-rich microdomains of the cell surface (Guzzi et al., 2002; Rimoldi et al., 2003) . To address whether the interactions between V 1b receptors and G proteins are random interactions or whether they are related to compartmentalization, we investigated the effects of M␤CD, a compound that rapidly removes more than half of the cholesterol content of the plasma membrane and disrupts rafts and caveolae (Kilsdonk et al., 1995) . Previous work has shown that M␤CD treatment does not prevent cAMP signaling (Miura et al., 2001) ; indeed, we found that it had no effect on forskolin-induced cAMP production. However, it did lower the maximal IP 1 accumulation and increased the maximal cAMP accumulation. Using AVT as the stimulating ligand in HEK-293 cells led to the same modifications. These modifications observed upon either AVP or AVT stimulation during M␤CD treatment probably reflect the number of receptors available for each pathway. The difference between CHO and HEK-293 cells with respect to cAMP accumulation after M␤CD treatment can most probably be attributed to a different compartmentalization and/or concentration of the transduction partners involved in the response to AVP, as previously reported for the ␤ 2 -adrenergic receptor (Huang et al., 2007) or the ␦-opioid receptor (Ostrom et al., 2002) . In fact, various interpretations can be proposed to explain the results: 1) the V 1b receptor could be localized to cholesterol-rich domains, where it could preferentially couple with G q/11 and activate the IP pathway upon AVP or AVT binding, and/or to other (non-cholesterol-rich) domains, where it could interact with G s and signal through the cAMP pathway; 2) G s or other proteins of the cAMP signaling cascade could be sequestered to cholesterol-rich domains, and the disruption of these microdomains with M␤CD could increase the available concentration of the sequestered proteins, facilitating the competition between the usual G q coupling of the V 1b receptor and the newly available G s coupling (Pontier et al., 2008) .
The presence of V 1b receptors has now been demonstrated in various brain regions. Their function has been recently highlighted. Indeed, the only currently available specific antagonist, SSR149415, was shown to exert anxiolytic and antidepressant effects in animal models (Serradeil-Le Gal et al., 2002) . However, nothing is known about how the V 1b receptor exerts its effects in the brain. The present work increases our understanding of V 1b pharmacology by showing that the receptor can activate two different signaling pathways depending on its localization within the plasma membrane. Furthermore, the observation that the relative intensities of agonist effects on the two signaling pathways vary strongly with their molecular structure opens new perspectives to the design of ligands that could be used to selectively activate or inhibit one or the other pathway and thereby specifically modulate particular V 1b receptor-regulated functions within the central nervous system.
